Skip to content

InMode

US · INMD #3410 by market cap Listed 2019
14.00 -0.01 -0.07%
Live - 5344 symbols - heartbeat 151s ago · 2026-10-08 09:57
Pre-market 13.99 -0.14%
After-hours 13.85 -1.12%
Market cap
805.62M
P/B
1.28
EPS
1.43
Reader sentiment Are you bullish or bearish on INMD?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Fair Value how this is computed

Near fair value
6.68 fair value ≈ 19.77 32.85
  • Implied fair-value range of 6.68-32.85, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -29.2% below the average-multiple fair value of 19.77.

Valuation each multiple against its own 5-year range

P/B ratio 1.28 Cheap vs history 3rd percentile
5-year average 3.90 · #33 of 125 in Medical Devices
P/E ratio 11.58 In line with history 57th percentile
5-year average 13.82 · forward 12.30 · #4 of 38 in Medical Devices
P/S ratio 2.15 Cheap vs history 1st percentile
5-year average 5.11 · forward 2.18 · #56 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
InMode (INMD) 805.62M 11.57 1.28 0.00%
Abbott Laboratories (ABT) 170.20B 31.83 3.33 2.48%
Medtronic (MDT) 111.50B 21.47 2.22 3.27%
Stryker Corp (SYK) 105.78B 28.58 4.41 1.26%
Boston Scientific (BSX) 60.66B 16.95 2.43 0.00%
Edwards Lifesciences (EW) 48.25B 48.67 4.54 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value15.47 Economic moatNone UncertaintyMedium

Trading 10.5% below Morningstar's fair value estimate.

Fair value

InMode Ltd is assigned a 4-star quantitative star rating, indicating our belief that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 9% discount to our quantitative fair value estimate of $15.47 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The company's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 77.6% sits in the top 40% globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are cheap.

The company's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 10.1%, a core component of profitability, ranks in the top 20% compared with global peers. This suggests that it is generating substantial earnings relative to its share price, which further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

By Quantitative Equity Report

Quote time 2026-10-08 09:57:48 · For reference only, not investment advice and not tailored to your situation.